<DOC>
	<DOCNO>NCT00207766</DOCNO>
	<brief_summary>A study infliximab patient Fistulizing Crohn 's Disease</brief_summary>
	<brief_title>A Study Safety Efficacy Infliximab ( Remicade ) Subjects With Fistulizing Crohn 's Disease</brief_title>
	<detailed_description>This medical research study patient Crohn 's disease one drain enterocutaneous fistula ( fistula bowel skin ) . Fistulas common complication Crohn 's disease . Fistulas rarely close spontaneously may get good treatment underlie Crohn 's disease . This study investigate safety efficacy maintenance dose anti-TNF ( anti-tumor necrosis factor ) antibody ( protein ) , call infliximab , compare placebo ( inactive substance ) providing sustain reduction number drain fistula . Subjects receive infliximab week 0 , 2 6 follow infusion infliximab 5 mg/kg placebo week 14 every 8 week week 46 . Patients lose response eligible increase treatment 5 mg/kg infliximab .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Single multiple drain fistula Crohn 's disease least 3 month ' duration , Crohn 's disease complication surgery might indicate Positive stool culture</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>infusion</keyword>
</DOC>